Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Document › Details

Theolytics Ltd.. (9/21/20). "Press Release: Theolytics Announces Appointment of Immatics' Carsten Reinhardt to its Board of Directors". Oxford.

Organisation Organisation Immatics Biotechnologies GmbH
  Group Immatics (Group)
Products Product oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy)
  Product 2 oncology
Persons Person Reinhardt, Carsten (Immatics 200910– CMO before Micromet 200506– CMO before Roche)
  Person 2 Casebourne, Charlotte (Theolytics 202107 CEO + Co-Founder)
     


Visionary oncology and biotech expert will help support progression of novel oncolytic viruses into cancer clinical trials


Theolytics, a biotech focused on developing curative cancer therapies in the form of best-in-class oncolytic viruses, today announced the Board appointment of Carsten Reinhardt MD PhD.

Dr Reinhardt is a visionary oncology and biotech expert, with extensive experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe. This includes bringing over 20 new compounds to IND stage, achieving various successful BLA filings, and, at Hoffmann-La Roche, having global responsibility for the development of Herceptin®. He also has a significant track record in financing biopharmaceutical companies, including successful public offerings (over USD 700m raised in private and public financing rounds) and has been instrumental in numerous deals with large pharmaceutical and biotech companies, achieving repeated deal values over USD 1bn. Further, Dr. Reinhardt, as Chair of the Advisory Board, was instrumental in the acquisition of oncolytic company Vira Therapeutics by Boehringer Ingelheim for up to EUR 210m.

CEO and co-founder Charlotte Casebourne said, "I am delighted that Carsten is joining our Board. His exceptional track-record in the immuno-oncology space, global clinical development and launch expertise, and financing track record brings a wealth of expertise to Theolytics. Carsten's contribution will be invaluable to us as we work to provide effective therapies for patients.

"Our revolutionary approach - harnessing Darwinian selection to optimise viruses as efficacious therapies, suitable for IV delivery - could transform treatment for cancers, especially those that are notoriously resistant to existing treatment options."

Dr Reinhardt, currently Chief Development Officer and Managing Director of NASDAQ-listed Immatics Biotechnologies GmbH said, "I very much look forward to working with Theolytics, a company that is revolutionizing the discovery and development of more effective and safer oncolytic virus therapies. The company's revolutionary adenoviral-based selection platform enables a target product profile led, highly specific approach to drug discovery and may overcome many of the current limitations of immuno-oncology."

Dr Reinhardt joins Theolytics' world-class team, which includes Chair, Dr Ken Powell, advisors Annalisa Jenkins, Susan Clement-Davies, and Co-founder/SAB Chair Professor Len Seymour.

For more details on the team please click here


Media contacts:

Theolytics
Charlotte Casebourne CEO
c.casebourne@theolytics.com

Scius Communications
Katja Stout
katja@sciuscommunications.com


About Theolytics

An Oxford, England, based medical biotech company, Theolytics is focused on developing curative cancer therapies in the form of best-in-class oncolytic viruses. The company is pioneering a novel approach to developing the most effective oncolytic viruses. Their platform generates candidates with enhanced efficacy and safety profiles in both liquid and solid tumors, suitable for intravenous delivery. The company was founded in December 2017, and is based in the BioEscalator Building, a biotech hub in the heart of Oxford for new and developing life science innovations, with access to world-class scientific expertise and capabilities in cancer therapeutics.


About Carsten Reinhardt MD PhD

Dr Reinhardt is the Chief Development Officer (CDO) and Managing Director of Immatics Biotechnologies GmbH, leading the company's product development strategy and with overall responsibility for the TCR Bispecifics platform and pipeline. He joined Immatics from Micromet Inc. where he was CMO and on the management board.

Prior to Micromet Inc., at Hoffmann-La Roche he had global responsibility for the development of Herceptin®, building on experience as Head of Clinical Development at Germany's Fresenius Biotech. He has extensive experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe. This includes bringing over 20 new compounds to IND stage, including

Blincyto® in acute lymphoblastic leukemia, Removab® in solid tumors, and various sBLA/MAA for Herceptin® in additional indications such as adjuvant breast cancer and gastric cancer.

He has a significant track record in financing biopharmaceutical companies including successful public offerings (over USD 700m raised in private and public financing rounds) and has been instrumental in numerous deals with large pharmaceutical and biotech companies, achieving repeated deal values over USD 1bn.

Before working in the biopharma industry, Dr Reinhardt held academic medical positions and worked at the University of Tuebingen and the Max Planck Institute. He has co-authored over 40 publications in peer-reviewed journals including Nature, Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine.

He was awarded a Medical Degree from Germany's University of Munich, with his PhD thesis being in Cellular Immunology at the Ludwig-Maximilians University of Munich. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy, the European Society of Medical Oncology, and he is a Visiting Professor for Pharmaceutical Medicine at the University of Basel.

   
Record changed: 2021-08-04

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Theolytics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top